These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 23179176

  • 1. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
    Stott CG, White L, Wright S, Wilbraham D, Guy GW.
    Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
    [Abstract] [Full Text] [Related]

  • 2. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.
    Stott CG, White L, Wright S, Wilbraham D, Guy GW.
    Eur J Clin Pharmacol; 2013 Apr; 69(4):825-34. PubMed ID: 23052407
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
    Fernández-Trapero M, Pérez-Díaz C, Espejo-Porras F, de Lago E, Fernández-Ruiz J.
    Biomolecules; 2020 Feb 11; 10(2):. PubMed ID: 32054131
    [Abstract] [Full Text] [Related]

  • 5. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P, Trojano M.
    Eur Neurol; 2016 Feb 11; 76(5-6):216-226. PubMed ID: 27732980
    [Abstract] [Full Text] [Related]

  • 6. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.
    Clin Neuropharmacol; 2018 Feb 11; 41(5):171-176. PubMed ID: 30024443
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
    Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA.
    Clin Chem; 2011 Jan 11; 57(1):66-75. PubMed ID: 21078841
    [Abstract] [Full Text] [Related]

  • 9. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J.
    Neurodegener Dis Manag; 2018 Jun 11; 8(3):151-159. PubMed ID: 29851356
    [Abstract] [Full Text] [Related]

  • 10. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ, Nurmikko TJ, Young CA.
    Clin Ther; 2007 Sep 11; 29(9):2068-79. PubMed ID: 18035205
    [Abstract] [Full Text] [Related]

  • 11. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Molnar A, Fu S, Lewis J, Allsop DJ, Copeland J.
    Forensic Sci Int; 2014 May 11; 238():113-9. PubMed ID: 24699310
    [Abstract] [Full Text] [Related]

  • 12. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
    Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA.
    Drug Alcohol Depend; 2013 Jun 01; 130(1-3):68-76. PubMed ID: 23146820
    [Abstract] [Full Text] [Related]

  • 13. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
    Montero-Escribano P, Vila Silván C.
    Expert Rev Med Devices; 2019 Sep 01; 16(9):835-840. PubMed ID: 31393179
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Fernández Ó.
    Eur Neurol; 2016 Sep 01; 75 Suppl 1():1-3. PubMed ID: 26901342
    [Abstract] [Full Text] [Related]

  • 16. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.
    Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F.
    J Anal Toxicol; 2005 Sep 01; 29(8):782-9. PubMed ID: 16356335
    [Abstract] [Full Text] [Related]

  • 17. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT.
    J Pain Symptom Manage; 2013 Aug 01; 46(2):207-18. PubMed ID: 23141881
    [Abstract] [Full Text] [Related]

  • 18. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L, Gidal B, Blakey G, Tayo B, Morrison G.
    CNS Drugs; 2018 Nov 01; 32(11):1053-1067. PubMed ID: 30374683
    [Abstract] [Full Text] [Related]

  • 19. A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.
    Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF.
    Clin Pharmacol Drug Dev; 2013 Jul 01; 2(3):285-94. PubMed ID: 27121791
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.